| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Bright Minds Biosciences (NASDAQ:DRUG) through any online brokerage.
Other companies in Bright Minds Biosciences’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Bright Minds Biosciences has a consensus price target of $130.88.
The stock price for Bright Minds Biosciences (NASDAQ: DRUG) is $54 last updated October 19, 2026 at 4:01 PM EDT.
There are no upcoming dividends for Bright Minds Biosciences.
Bright Minds Biosciences does not have any upcoming earnings scheduled.
There is no upcoming split for Bright Minds Biosciences.
Bright Minds Biosciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
